Innovative biotech firm Rebiotix snapped up by Swiss drugmaker

5 April 2018

Privately-held Swiss firm Ferring Pharmaceuticals on Wednesday closed a deal toacquire USA-based Rebiotix, a development-stage biotechnology company focusing on the treatment of gastrointestinal diseases by developing human microbiome.

This acquisition, financial terms of which are not disclosed, brings together two innovative healthcare companies that share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients, noted Ferring.

The most advanced investigational microbiome treatment from Rebiotix is RBX2660, a non-antibiotic treatment currently in Phase III development for the prevention of recurrent clostridium difficile (CDI). RBX2660 has the potential to be the first human microbiome product approved anywhere in the world. In the USA, RBX2660 has received Food and Drug Administration Fast Track, Breakthrough Therapy and Orphan Drug designations, which means the FDA considers it eligible for Expedited Review, once the submission has been made.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK